Bio-Rad Laboratories (BIO) Projected to Post Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Bio-Rad Laboratories to post earnings of $2.57 per share and revenue of $694.6380 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Bio-Rad Laboratories Stock Up 2.5%

Shares of NYSE:BIO opened at $306.53 on Thursday. The firm has a market capitalization of $8.27 billion, a PE ratio of -12.61 and a beta of 1.18. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $351.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.44 and a quick ratio of 3.94. The firm’s 50-day moving average is $309.69 and its two-hundred day moving average is $299.35.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BIO shares. Wells Fargo & Company upped their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, Citigroup upped their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $358.50.

Institutional Trading of Bio-Rad Laboratories

Several institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. raised its stake in Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Quarry LP grew its holdings in shares of Bio-Rad Laboratories by 131.5% during the third quarter. Quarry LP now owns 287 shares of the medical research company’s stock worth $80,000 after purchasing an additional 163 shares during the last quarter. CIBC Private Wealth Group LLC increased its position in shares of Bio-Rad Laboratories by 241.2% during the third quarter. CIBC Private Wealth Group LLC now owns 331 shares of the medical research company’s stock worth $93,000 after purchasing an additional 234 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $211,000. Finally, WFA of San Diego LLC acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at about $222,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.